The pathway ahead in melanoma trials

Oncology (Williston Park). 2009 May;23(6):496, 498, 500.

Authors

Arlo J Miller¹, Svetomir N Markovic, Paul Haluska Jr

Affiliation

¹ Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 19544690

No abstract available

Publication types

Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Clinical Trials as Topic
Cyclin-Dependent Kinase 4 / genetics
Cyclin-Dependent Kinase Inhibitor p16 / genetics
Genes, p16
Humans
Melanoma / blood supply
Melanoma / drug therapy*
Melanoma / genetics*
Melanoma / metabolism
Mutation
Neovascularization, Pathologic
Proto-Oncogene Proteins B-raf / genetics
Skin Neoplasms / blood supply
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics*
Skin Neoplasms / metabolism
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vascular Endothelial Growth Factor A / metabolism
ras Proteins / genetics

Substances

Angiogenesis Inhibitors
Cyclin-Dependent Kinase Inhibitor p16
Vascular Endothelial Growth Factor A
BRAF protein, human
Proto-Oncogene Proteins B-raf
Cyclin-Dependent Kinase 4
ras Proteins